Загрузка...
Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
PURPOSE: To review published evidence for a treatment interval extension to ≥12-weeks in neovascular macular degeneration treated with intravitreal Aflibercept. METHODS: A systematic search was performed in the NCBI/PubMed database to identify pro- and retrospective studies retrieved by the key term...
Сохранить в:
| Опубликовано в: : | Clin Ophthalmol |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6650619/ https://ncbi.nlm.nih.gov/pubmed/31409968 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S185756 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|